Grace Therapeutics (GRCE) Return on Capital Employed (2020 - 2026)
Grace Therapeutics (GRCE) posted Return on Capital Employed of 16.93% for Q1 2026, little changed sequentially from 16.98% in Q4 2025, and up 886.0% YoY from 1.72% in Q1 2025.
Grace Therapeutics (GRCE) Return on Capital Employed (2020 - 2026) Analysis & Trends
Grace Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 16.93% in Q1 2026.
- Quarterly Return on Capital Employed rose 886.0% year-over-year to 16.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.93% (up 886.0% YoY) and the FY2026 annual result came in at 16.49%, up 710.0% from the prior year.
- Return on Capital Employed was little changed at 16.93% in Q1 2026 per GRCE's latest filing, from 16.98% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 13.19% in Q1 2022 and troughed at 70.0% in Q2 2023.
- A 5-year average of 29.54% and a median of 19.39% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 5605 bps in 2023, then surged 5061 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 16.02% in 2022, then plunged by 295 bps to 63.19% in 2023, then jumped by 57 bps to 27.34% in 2024, then jumped by 38 bps to 16.98% in 2025, then advanced by 0 bps to 16.93% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 16.93%, 16.98%, and 18.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - | -41.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.86% |
| Mar 31, 2026 | -16.93% |
| Dec 31, 2025 | -16.98% |
| Sep 30, 2025 | -18.68% |
| Jun 30, 2025 | -21.59% |
| Mar 31, 2025 | -25.79% |
| Dec 31, 2024 | -27.34% |
| Sep 30, 2024 | -24.82% |
| Jun 30, 2024 | -19.39% |
| Mar 31, 2024 | -17.59% |
| Dec 31, 2023 | -63.19% |
| Sep 30, 2023 | -65.83% |
| Jun 30, 2023 | -70.00% |
| Mar 31, 2023 | -55.16% |
| Dec 31, 2022 | -16.02% |
| Sep 30, 2022 | -15.71% |
| Jun 30, 2022 | -13.95% |
| Mar 31, 2022 | -13.19% |
| Dec 31, 2021 | -11.82% |
| Sep 30, 2021 | -12.82% |